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Abstract
Background Atrial fibrillation (AF) is the most common
cardiac arrhythmia and is associated with a heavy burden
of morbidity and mortality, mainly due to an increased risk
of cerebrovascular events and cardiac failure. Oral anti-
coagulant (OAC) treatment prevents stroke and systemic
thromboembolism in patients with AF and its use is
strongly recommended in guidelines. However, its use in
this patient group remains limited. Primary care physicians
(PCPs) have an important role to play in this context.
Objective The primary objective was to estimate preva-
lence and epidemiological features of AF in the primary
care setting, focusing on ischaemic and bleeding risk
assessment. A secondary objective was to examine the
PCPs’ level of adherence to the guidelines for the pre-
vention of thromboembolic risk in these patients.
Methods This retrospective, observational study was
based on data entered by 128 PCPs into the Health Search
(HS) Thales database, identifying patients with a diagnosis
of AF at the time of the analysis.
Results Out of 167,056 patients analysed, 2,173 (1.3 %)
were diagnosed with AF, with 86 % at high risk for
ischaemic stroke, according to CHA2DS2-VASc (conges-
tive heart failure, hypertension, age C75 years [doubled],
diabetes, stroke [doubled], vascular disease, age 65–74
years, sex category [female]) stratification. After the
diagnosis of AF, 84 % of patients were prescribed OAC
treatment. However, at 2 years’ follow-up, only 29.6 %
were still being treated with OACs.
Conclusion The prevalence of AF in this analysis was
consistent with previously reported Italian national epide-
miological data. Adherence to the European Society of
Cardiology AF guidelines by PCPs was low, despite the
high levels of stroke risk. At the end of the observation
period less than one-third of patients were still on OAC
therapy. Awareness of the benefits of OACs in stroke
prevention in AF patients needs to be improved.
1 Introduction
Atrial fibrillation (AF) is the most common cardiac
arrhythmia observed in clinical practice. It is associated with
a heavy burden of morbidity and mortality, mainly due to an
increased risk of cerebrovascular events and cardiac failure.
The prevalence of AF in the general population increases
exponentially with age (approximately 0.4 % in the general
population, 3–5 % in subjects aged[65 years and 10 % in
subjects aged[80 years) [1, 2]. AF is associated with a high
risk of systemic thromboembolism, of which stroke is the
most frequent manifestation [1–5]. Recently, it has been
hypothesized that AF can be a threat to the brain not only
because of the risk of stroke, but also because it leads to
cognitive deterioration resulting in dementia, even without
first having developed a stroke [6, 7].
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The efficacy of oral anticoagulant (OAC) treatment in
the prevention of stroke and systemic thromboembolism
has been demonstrated in randomized controlled trials [8]
and is strongly recommended in the guidelines from the
European Society of Cardiology (ESC) [3]. Despite strong
evidence of the efficacy of OAC treatment, its use in
clinical practice for prevention of thromboembolism in
patients with AF is still limited [9, 10]. Although diag-
nostic and therapeutic strategies in AF patients are usually
initiated by cardiologists or other in-hospital specialists,
management of co-morbidities and drug adherence also
involves primary care physicians (PCPs). In this context,
prevention of thromboembolism associated with AF is an
essential component of the global cardiovascular preven-
tion strategy in primary care.
A Canadian registry showed limited use of the CHADS2
(cardiac failure, hypertension, age, diabetes, stroke [dou-
bled]) score by family physicians for assessing the need for
anticoagulant therapy for stroke prevention in AF patients
[4, 11]. A number of other observational studies in the
primary care setting have also found that adherence to
guidelines for stroke prevention in patients with AF is low
and that anticoagulation is underused [9, 12]. Moreover,
even when warfarin is prescribed, achievement of target
International Normalized Ratio (INR) 2.0–3.0 is inade-
quate [13]. The primary objective of this study was to
estimate the prevalence and epidemiological features of AF
in this population with a focus on ischaemic and bleeding
risk assessment. A secondary objective was to examine the
PCPs’ level of adherence to the guidelines for the pre-
vention of thromboembolic risk in these patients.
2 Methods
Data were obtained from 128 PCPs in Naples who provided
information to the Health Search (HS)/Thales database. We
performed an observational, retrospective analysis of
patients with a diagnosis of AF over a 2-year period (April
2009–April 2011). Institutional Review Board/Ethics
Committee approval is not required for retrospective,
observational studies based on database analysis in Italy.
2.1 Health Search (HS)/Thales Database
The HS/Thales database is an Italian general practice
registry that collects data from the electronic patient
records of a selected group of Italian PCPs who voluntarily
agreed to collect patient information and to attend specific
training courses on data entry. In the HS/Thales database
patient demographic details are linked with a range of
clinical parameters (e.g., diagnosis, diagnostic procedures,
drug prescription information, hospital admissions) by the
use of an encrypted patient code. The research validity of
the HS/Thales database has been confirmed by a number of
published comparative studies [14–16].
2.2 Study Population
All subjects C18 years of age recorded in the database in
April 2009 were included in the analysis if they persisted
with the same PCP for at least 1 year after the index
diagnosis. We identified patients with a diagnosis of AF
according to the International Classification of Diseases,
9th revision, Clinical Modification (ICD-9-CM) [items
427.3 and 427.32] [17]. However, diagnoses derived from
electronic medical records did not distinguish between
paroxysmal, persistent or permanent AF, or patients whose
AF subsequently resolved.
In order to reduce potential bias due to the missing
diagnoses of AF, use of amiodarone, dronedarone, flecai-
nide, sotalol and warfarin was considered as potential
markers of AF and matched with diagnostic and electro-
cardiography (ECG) findings. Demographic and clinical
data (risk factors, co-morbidities) were collected for all the
enrolled subjects, and diagnostic procedures and thera-
peutic management were also analysed for patients with a
diagnosis of AF. Co-morbidities and risk factors for car-
diovascular events were identified according to the ICD-9-
CM. Risk stratification of patients was performed with the
CHADS2 and CHA2DS2-VASc (congestive heart failure,
hypertension, age C75 years [doubled], diabetes, stroke
[doubled], vascular disease, age 65–74 years, sex category
[female]) scores for ischaemic risk [18] and HAS-BLED
(hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile INR, elderly
[ 65 years], drugs/alcohol concomitantly) score [19] for
bleeding risk in accordance with ESC guidelines [3]. In
addition, we compared the patients’ HAS-BLED and
ATRIA (anticoagulation and risk factors in atrial fibrilla-
tion) [20] scores. Predefined algorithms for the automatic
calculation of these scores were applied. Biochemical
analysis and instrumental diagnostic procedures (ECG,
echocardiography) were carried out at specialist centres
and recorded in the database. Since this was an observa-
tional study, no additional diagnostic or therapeutic inter-
ventions were performed.
2.3 Statistical Analyses
Due to the observational nature of the study a formal cal-
culation of the study sample size was not applicable and
only descriptive analyses were performed. Standardized
definitions of all patient-related variables were used and
clinical diagnoses were assessed according to the ICD-
9-CM system. Categorical variables are presented as
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percentage and comparisons were performed using a Chi-
squared (v2) test.
3 Results
A total of 2,173 patients (out of 167,056 eligible subjects
enrolled in the HS/Thales database) had a diagnosis of AF
(1.3 %) and details of their demographic and clinical
characteristics at baseline are shown in Table 1. The
prevalence of AF was highest in women (women 1.4 % vs
men 1.2 %), and in the age group C75 years (6.9 % vs
3.5 % in patients aged\75 years). The majority of patients
with AF were regular smokers (85.3 %) and had a history
of hypertension (75.5 %). Diabetes mellitus and thyroid
dysfunction were observed in 24.3 % and 29.5 % of
patients, respectively. Other risk factors commonly asso-
ciated with AF (valvular heart disease and chronic
obstructive pulmonary disease [COPD]) were more fre-
quent among patients with AF compared with patients
without AF (COPD 10.9 % vs 2.6 %, respectively; valvular
heart disease 9.5 % vs 2.4 %, respectively). Notably, 9.9 %
of patients with AF had an anamnestic diagnosis of heart
failure, compared with 0.6 % in the overall population. AF
patients were also more likely to have a history of previous
transient ischaemic attack (TIA) or stroke than patients
without AF (p \ 0.001). Echocardiographic evaluations
were carried out on 490 patients with AF (22.5 %), and
findings suggestive of some structural anomaly were
reported in 240 cases (49 %).
Assessment of the AF patients’ CHADS2 scores indi-
cated that 20 % of patients were at high risk for ischaemic
stroke, compared with 68.6 % at moderate risk (Fig. 1). In
accordance with the current ESC AF guidelines [3], the
ischaemic risk was also calculated using CHA2DS2-VASc
scores, which indicated that 4.3 % of patients with AF
were at low risk of ischaemic stroke, 9.7 % were at mod-
erate risk, and 86 % were at high risk (Fig. 1). According
to the HAS-BLED score [19], 35.2 % of patients were at
high risk of bleeding (Fig. 2), while the recently validated
ATRIA score [20] indicated that 82.2 % were at low risk of
bleeding (0–3), 3.5 % were at intermediate risk (5), and
14.3 % were at high risk (C5) (Fig. 3).
Of the 2,173 patients with AF, 84 % (n = 1,827) took
OAC treatment at the time of diagnosis. Among patients on
OAC treatment, 91 % had a CHA2DS2-VASc score C2,
7.3 % were at moderate risk and 1.7 % were at low risk;
similar rates were observed for antiplatelet drugs. How-
ever, at the 2-year follow-up, 64.8 % of patients
(n = 1184) had discontinued OACs in favour of anti-
platelet treatment and only 29.6 % (n = 643) were still
being treated with OACs. INR values were available in the
database for only 620 patients but the majority of them
(63.2 %; n = 392) were not within the target therapeutic
range for AF (INR 2.0–3.0) at the last recorded
examination.
4 Discussion
AF is the most common cardiac arrhythmia, conferring
substantial mortality and morbidity from stroke, thrombo-
embolism and heart failure, and significant impairment of
quality of life [21, 22]. However, as it is often asymp-
tomatic, its prevalence is underestimated. It has been sug-
gested that a regular pulse measurement followed by ECG
can detect a number of additional cases in comparison with
the current clinical practice [23].
The prevalence of AF has been strongly associated with
increasing age, affecting about 5 % of people over 65 years
of age and 9 % of people aged more than 80 years [1, 24].
The results of an observational cohort study of 1,599 Italian
patients aged C65 years showed a 7.4 % prevalence for AF
[25]. In our study we have reported a 6.9 % prevalence in
patients C75 years. In contrast to epidemiological data
from the literature, which has indicated a higher rate of AF
in men [1], we observed a higher prevalence in women,
which can probably be attributed to a higher number of
visits to PCPs by female patients.
According to the ESC guidelines, the CHADS2 score
should be used as an initial, rapid and easy-to-remember
means of assessing stroke risk [3]. A limitation to the use of
the CHADS2 score is that it only includes a few stroke risk
factors; as a result more ‘moderate-risk patients’ (with a
CHADS2 score of 1) could potentially derive greater
benefit with OAC therapy compared with aspirin (acetyl-
salicylic acid). In order to improve the choice of anti-
thrombotic strategy in non-valvular AF, some ‘stroke risk
modifier’ risk factors have been added to the CHADS2
score, thus deriving a more refined stroke risk stratification,
named CHA2DS2-VASc. This scheme identifies ‘truly low
risk’ atrial fibrillation patients as those with a CHA2DS2-
VASc score of 0, who can probably be treated with no
antithrombotic therapy. All others (i.e., CHA2DS2-VASc
score of 1), can be considered for oral anticoagulation [18].
The ESC guidelines suggest that the CHA2DS2-VASc
score should be assessed in all patients presenting with at
least one stroke risk factor (resulting in ‘moderate risk’)
according to the CHADS2 score [3].
In our analysis, stroke risk stratification according to
CHADS2 showed that 20 % of AF patients were at high
risk but, when stratified by the more refined CHA2DS2-
VASc scores, the proportion at high risk of stroke increased
up to 86 %.
The patient’s risk of bleeding should also be evaluated
prior to the initiation of OAC treatment, and the
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HAS-BLED score should be used for this purpose. A HAS-
BLED score of C3 indicates ‘high bleeding risk’ and some
caution and regular review of the patient is needed fol-
lowing the initiation of antithrombotic therapy, whether
with oral anticoagulation or aspirin [3]. The HAS-BLED
score was derived and validated in an AF population and its
predictability has been recently compared to the HE-
MORR2HAGES (hepatic or renal disease, ethanol use,
malignancy, older age [ 75 years], reduced platelet count,
re-bleeding [doubled], hypertension uncontrolled, anaemia,
genetic factors, elevated risk of fall, stroke) score [26].
Both of these schemes performed similarly in predicting
major bleeding, but a substantial advantage of HAS-BLED
is its relative simplicity, allowing ease of use in everyday
clinical practice [19, 26].
It has been suggested that the ATRIA score (including
five weighted risk factors: anaemia, severe renal disease,
age 75 years and older, previous haemorrhage, and diag-
nosed hypertension) may be used to support the choice of
antithrombotic strategy in patients at moderate ischaemic
risk, especially in view of the introduction of the novel
OACs. We compared the results from HAS-BLED to
ATRIA and found that the latter identified a lower number
of high risk patients. A debate has recently followed the
ATRIA score publication, as some concerns have been
raised with regard to the derivation of the new schema and
its applicability. In particular, inclusion criteria and risk
factors from which the model was derived have been
criticized. Because of the selection of a ‘warfarin-experi-
enced’ cohort in the study, ATRIA might not be applicable








No. of patients % No. of patients % No. of patients %
All subjects 2,173/167,056 1.3 164,883/167,056 98.7
Male 78,767/167,056 47.2 964/78,767 1.2 77,803/78,767 98. 8
Female 88,289/167,056 52.8 1,209/88,289 1.4 87,080/88,289 98.6
\65 years 131,535/167,056 78.7 372/131,535 0.3 131,163/131,535 99.7
C65 to \74 years 17,761/167,056 10.6 572/17,761 3.2 17,189/17,761 96.8
C75 years 17,760/167,056 10.6 1,229/17,760 6.9 16,531/17,760 93.1
BMI [30 kg/m2 10,768/57,691 18.7 403/1,533 26.3 10,365/56,158 18.5
BMI 25–30 kg/m2 20,973/57,691 36.3 631/1,533 41.2 20,342/56,158 36.2
BMI \25 kg/m2 25,950/57,691 45.0 499/1,533 32.5 25,451/56,158 45.3
Smoker 14,812/167,056 8.9 1,854/2,173 85.3 12,958/164,883 7.9 \0.001
Alcoholism 53/167,056 0.03 2/2,173 0.19 51/164,883 0.03 0.11
eGFR C60 mL/min/1.73 m2 12,406/20,696 59.9 305/872 35.0 12,102/19,825 61.0 \0.001
eGFR \60 mL/min/1.73 m2 8,290/20,696 40.1 567/872 65.0 7,723/19,825 39.0 \0.001
History of hypertension 45,438/167,056 27.2 1,641/2,173 75.5 43,797/164,883 26.5 \0.001
Heart failure 1,270/167,056 0.8 216/2,173 9.9 1,054/164,883 0.6 \0.001
Valvular defect 1,755/167,056 1.0 207/2,173 9.5 1,548/164,883 0.93 \0.001
Congenital heart defect 115/167,056 0.1 4/2,173 0.2 111/164,883 0.1 \0.001
Acquired cardiomyopathies 93/167,056 0.1 14/2,173 0.6 79/164,883 0.05 \0.001
Coronary heart disease 179/167,056 0.1 10/2,173 0.5 169/164,883 0.1 \0.001
Diabetes mellitus 12,956/167,056 7.7 528/2,173 24.3 12,428/164,883 7.5 \0.001
Dyslipidaemias 22,837/167,056 13.7 668/2,173 30.7 22,169/164,883 13.4 \0.001
Thyroid dysfunction 23,596/167,056 14.1 641/2,173 29.5 22,955/164,883 13.9 \0.001
COPD 4,529/167,056 2.7 237/2,173 10.9 4,292/164,883 2.6 \0.001
Sleep apnoea 1,197/167,056 0.7 47/2,173 2.2 1,150/164,883 0.7 \0.001
Previous stroke/TIA 23/167,056 0.0 4/2,173 0.2 19/164,883 0.01 \0.001
Anaemia (Hb \13 g/dL males,
Hb \12 g/dL females)
28,046/167,056 16.8 818/2,173 37.6 27,228/164,883 16.5 \0.001
History of bleeding 4,876/167,056 2.9 133/2,173 6.1 4,743/164,883 2.9 \0.001
AF atrial fibrillation, BMI body mass index, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate,
Hb haemoglobin, TIA transient ischaemic attack
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in warfarin-naı¨ve patients, notoriously at higher risk of
bleeding [27]. Thus, to date, the use of the ATRIA score
does not seem to be considered as an alternative to the
HAS-BLED score for stratification of bleeding risk.
Many observational studies have shown that in clinical
practice OACs are frequently underutilized, with reported
percentages of prescriptions between 30 and 60 % despite
the recognized clinical benefits of prevention of AF-related
strokes [28–30]. A previous Italian primary care registry
[31] has shown a significantly lower proportion of AF
patients treated with OACs (persistence with OAC was
\50 % at 1 year and reduced to approximately 25 % by
2 years), when compared with the Euro Heart Survey of
AF patients [28] or other European Countries [32]. In our
analysis, despite a higher percentage of OAC prescriptions
following the diagnosis of AF, levels of adherence among
the PCPs’ patients were very low with less than one-third
of patients maintained on warfarin at the end of the 2-year
follow-up. Notably, INR values were recorded in a
minority of cases and were not within the target therapeutic
range in most of them.
The underutilization of OAC therapy may also be
explained by a lack of awareness of patient risk stratifica-
tion criteria or poor appreciation of the risk–benefit ratio of
OACs, with an overestimation of their bleeding risks
[9, 13]. Moreover, this may reflect the difficulty of man-
aging patients on conventional OAC treatment regimens.
INR monitoring is important for management of OACs
currently used in clinical practice but is not easy to arrange
for all patients due to the need for regular blood tests and
frequent dose adjustments. Furthermore, the established
OACs have a narrow therapeutic range and exhibit a wide
variability of patient response, which leads many patients
to spend significant amounts of time outside the therapeutic
INR range and may favour drug discontinuation. Response
variability itself may represent a barrier to prescribing,
particularly in the elderly [33]. Thus, thromboembolic risk
stratification only partially influences the choice of the
OAC therapy for stroke prophylaxis and is underutilized,
even in high-risk patients. An Italian survey of anti-
thrombotic therapy in patients with AF showed that treat-
ment was discontinued in one-third of patients due to fear
of bleeding and difficulty in performing adequate moni-
toring [31].
The lack of use of OAC therapy is particularly evident
in elderly patients who were also at highest risk of stroke.
Even when there is evidence that age and AF indepen-
dently increase stroke risk, elderly people with AF are less
likely to receive OAC therapy. Recently, Olesen et al.
demonstrated in a nationwide cohort analysis in Denmark
that the net clinical benefit was more positive in patients at
high bleeding risk, and the absolute benefit in reducing
stroke with warfarin would outweigh the small increase in
Fig. 1 Stratification of ischaemic stroke risk in patients with atrial
fibrillation based on CHADS2 and CHA2DS2-VASc scores
(n = 2,173). CHADS2 cardiac failure, hypertension, age, diabetes,
stroke (doubled); CHA2DS2-VASc congestive heart failure, hyperten-
sion, age C75 years (doubled), diabetes, stroke (doubled), vascular
disease, age 65–74 years, sex category (female)
Fig. 2 Risk of bleeding in patients with atrial fibrillation based on
HAS-BLED score (n = 2,173). HAS-BLED hypertension, abnormal
renal/liver function, stroke, bleeding history or predisposition, labile
International Normalized Ratio, elderly ([65 years), drugs/alcohol
concomitantly
Fig. 3 Risk of bleeding in patients with AF based on ATRIA score
(n = 2,173). AF atrial fibrillation; ATRIA anticoagulation and risk
factors in atrial fibrillation
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intracranial haemorrhage with warfarin [34]. BAFTA
(Birmingham Atrial Fibrillation Treatment of the Aged
Study) showed that warfarin significantly reduces stroke
risk in the elderly [35]. In the ATRIA cohort, Singer et al.
also showed a reduction in absolute stroke risk with war-
farin: the benefit was greater in very elderly patients (age
C85 years) and among those at high stroke risk [36]. The
bleeding risk with antiplatelet therapy is similar to that
with warfarin, especially in the elderly who can benefit
most, in terms of risk of bleeding, from the accurate use of
OAC treatment, as compared with the use of antiplatelet
treatments [9, 35, 37]. The recent European position doc-
ument on bleeding risk assessment and management in AF
states that ‘‘bleeding risk is almost inevitably lower than
stroke in patients with AF’’ but can be minimized by
refining antithrombotic therapy in patients identified to be
at high risk [33].
This study was subject to a number of limitations.
Firstly, data were collected retrospectively and the analysis
was based on the diagnoses recorded by the PCPs in their
database, which may affect the accuracy in reporting
anamnestic data. Nevertheless, since it was our intent to
describe the epidemiology and management of AF patients
referred to PCPs, these data represent a picture of ‘real
world’ clinical practice in this setting. A second issue is
that in Italy there are some local directives and restrictions
affecting the prescription of drugs and diagnostic proce-
dures that could potentially influence physicians’ behav-
iour, which may limit the generalizability of these results to
a non-Italian population. This survey does not provide
information on outcomes and the potential relationship
with management strategies, and cannot be considered a
study on the appropriateness of diagnostic or therapeutic
approaches in patients with AF as the aim was to provide
epidemiological data in the PCP setting.
5 Conclusion
This study provides confirmation of previous epidemio-
logical data on AF prevalence in Italy [31]. Despite the
high stroke risk in this population, anticoagulant therapy is
underutilized, although, in comparison with other obser-
vational studies, we found a higher rate of OAC prescrip-
tion at the time of the diagnosis. In contrast, we detected a
very high rate of drug discontinuation and poor attention to
monitoring of the effectiveness of OAC therapy by mea-
surement of patients’ INR values.
In ‘real world practice’, evaluation of ischaemic and
bleeding risks, which should direct therapeutic decisions
concerning the prevention of thromboembolism in AF
patients, are not balanced and often the choice to avoid
OAC therapy is led by an overestimation of the
haemorrhagic risk. In addition, the management of chronic
OAC therapy using INR monitoring appears to represent a
real challenge in the PCP setting. The utilization of simple
risk scores could provide more sensitive instruments for a
real risk profile definition in these patients, and support
physicians’ therapeutic decisions in the primary care set-
ting. Our results strengthen the importance of promoting
educational programmes amongst PCPs, focusing on risk
stratification and adequate monitoring of patients on OAC
therapy. How much the availability of novel OACs will
change prevention strategies in this setting is still unknown.
However, even in this new landscape, net clinical benefit in
stroke prophylaxis will remain bound to balancing
ischaemic and bleeding risk.
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